Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of beta amino acids and derivatives. It features a sulfonamide group and is structurally related to benzoic acids. The molecule has been studied as an experimental compound, with no current approved medical indications or clinical use. Its mechanism of action includes inhibition of caspase enzymes, specifically caspase‑3, which plays a key role in apoptosis (programmed cell death). This makes it potentially useful for research into apoptosis-related diseases or as a biochemical tool in laboratory settings[5]. There are no known brand names or marketed formulations for this substance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-[4-(1-carboxymethyl-2-oxo-propylcarbamoyl)-benzylsulfamoyl]-2-hydroxy-benzoic acid.